Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Trump’s quest for Greenland could make Ozempic even more expensive
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.
Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
devdiscourse1d
Denmark's Diplomatic Push: Navigating Greenland Tensions
Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...
Novo Nordisk, other companies meet Danish prime minister following Trump's Greenland threat
The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
The New Republic on MSN4dOpinion
Trump Could Frankly Learn a Lot From Denmark
Indeed, Ozempic and Wegovy may well be in the news in the coming months—if Trump imposes the massive tariffs on Denmark that ...
Jim Cramer on Novo Nordisk A/S (NVO): ‘That’s Denmark’s Jugular’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...